| Christopher J Charbonnet, MD | |
|
1530 E Chevy Chase Dr, Suite 204, Glendale, CA 91206-4163 | |
| (818) 241-7246 | |
| (818) 241-1639 |
| Full Name | Christopher J Charbonnet |
|---|---|
| Gender | Male |
| Speciality | Interventional Pain Management |
| Experience | 32 Years |
| Location | 1530 E Chevy Chase Dr, Glendale, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225049968 | NPI | - | NPPES |
| 00G791310 | Medicaid | CA | |
| 00G791310 | Other | CA | BLUE SHIELD |
| Facility Name | Location | Facility Type |
|---|---|---|
| Pinnacle Home Health Care, Inc | Burbank, CA | Home health agency |
| Glendale Adventist Medical Center | Glendale, CA | Hospital |
| White Memorial Medical Center | Los angeles, CA | Hospital |
| Usc Verdugo Hills Hospital | Glendale, CA | Hospital |
| Glendale Mem Hospital & Hlth Center | Glendale, CA | Hospital |
| Entity Name | Westlake Pain Management Medical Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982711677 PECOS PAC ID: 3173511748 Enrollment ID: O20040503001240 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced the launch of a Phase 1 dose-escalation study of Debio 1450 (previously known as AFN-1720), a highly potent anti-infective agent that is selectively active against a large number of Staphylococcus species, including all known resistant strains such as methicillin-resistant S. aureus (MRSA) and vancomycin-intermediate S. aureus (VISA).
The quality of the emotional relationship between a mother and her young child could affect the potential for that child to be obese during adolescence, a new study suggests.
A new study of genetically modified immune cells by scientists from UCLA and the California Institute of Technology could help improve a promising treatment for melanoma, an often fatal form of skin cancer.
Researchers from Aarhus University have taken an important step in the fight against sleeping sickness, a disease that is a major problem in parts of Africa. According to the World Health Organization, the disease threatens approximately 60 million people and the treatment options are poor.
› Verified 4 days ago
| Entity Name | Christopher J Charbonnet Md A Professional Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679785695 PECOS PAC ID: 6002986122 Enrollment ID: O20080602000460 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced the launch of a Phase 1 dose-escalation study of Debio 1450 (previously known as AFN-1720), a highly potent anti-infective agent that is selectively active against a large number of Staphylococcus species, including all known resistant strains such as methicillin-resistant S. aureus (MRSA) and vancomycin-intermediate S. aureus (VISA).
The quality of the emotional relationship between a mother and her young child could affect the potential for that child to be obese during adolescence, a new study suggests.
A new study of genetically modified immune cells by scientists from UCLA and the California Institute of Technology could help improve a promising treatment for melanoma, an often fatal form of skin cancer.
Researchers from Aarhus University have taken an important step in the fight against sleeping sickness, a disease that is a major problem in parts of Africa. According to the World Health Organization, the disease threatens approximately 60 million people and the treatment options are poor.
› Verified 4 days ago
| Entity Name | Glendale Adventist Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831188275 PECOS PAC ID: 4284692096 Enrollment ID: O20110510000465 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced the launch of a Phase 1 dose-escalation study of Debio 1450 (previously known as AFN-1720), a highly potent anti-infective agent that is selectively active against a large number of Staphylococcus species, including all known resistant strains such as methicillin-resistant S. aureus (MRSA) and vancomycin-intermediate S. aureus (VISA).
The quality of the emotional relationship between a mother and her young child could affect the potential for that child to be obese during adolescence, a new study suggests.
A new study of genetically modified immune cells by scientists from UCLA and the California Institute of Technology could help improve a promising treatment for melanoma, an often fatal form of skin cancer.
Researchers from Aarhus University have taken an important step in the fight against sleeping sickness, a disease that is a major problem in parts of Africa. According to the World Health Organization, the disease threatens approximately 60 million people and the treatment options are poor.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher J Charbonnet, MD Po Box 5486, Orange, CA 92863-5486 Ph: (818) 550-0900 | Christopher J Charbonnet, MD 1530 E Chevy Chase Dr, Suite 204, Glendale, CA 91206-4163 Ph: (818) 241-7246 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced the launch of a Phase 1 dose-escalation study of Debio 1450 (previously known as AFN-1720), a highly potent anti-infective agent that is selectively active against a large number of Staphylococcus species, including all known resistant strains such as methicillin-resistant S. aureus (MRSA) and vancomycin-intermediate S. aureus (VISA).
The quality of the emotional relationship between a mother and her young child could affect the potential for that child to be obese during adolescence, a new study suggests.
A new study of genetically modified immune cells by scientists from UCLA and the California Institute of Technology could help improve a promising treatment for melanoma, an often fatal form of skin cancer.
Researchers from Aarhus University have taken an important step in the fight against sleeping sickness, a disease that is a major problem in parts of Africa. According to the World Health Organization, the disease threatens approximately 60 million people and the treatment options are poor.
› Verified 4 days ago
Dr. Christopher K Kaypekian, M.D. Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 1500 S Central Ave, Suite 126, Glendale, CA 91204 Phone: 818-409-0060 Fax: 818-409-0066 | |
Dr. Laszlo Z Galffy, M.D. Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 1505 Wilson Ter, Suite 170, Glendale, CA 91206 Phone: 818-244-3572 Fax: 818-244-8317 |